Tesamorelin 
GH / Fat Loss Peptide

10mg bottle

The Growth Hormone Releasing Hormone Analogue, Tesamorelin, Decreases Muscle Fat and Increases Muscle Area in Adults with HIV - PMC

In November 2010, the United States Food and Drug Administration approved tesamorelin for the treatment of excessive abdominal fat in PLWH (20). Tesamorelin is a synthetic growth hormone-releasing hormone that acts on the anterior pituitary gland to stimulate the endogenous growth hormone secretion (21). In randomized, controlled, double-blinded studies, tesamorelin decreased VAT by approximately 15% compared to placebo (22, 23, 24). In a separate study, tesamorelin reduced hepatic fat by a relative 40% (25) among PLWH with abdominal fat accumulation, compared to a 27% increase in the placebo arm. Ongoing studies are investigating the long-term safety of tesamorelin and the impact of tesamorelin on cognition, liver inflammation, and diabetic retinopathy in PLWH. The goals of this exploratory secondary analysis were to determine the effects of tesamorelin on muscle quality, as measured by changes in computed tomography (CT)-based trunk muscle density, a biopsy-correlated measurement of skeletal muscle fat (26), and trunk muscle area. We hypothesized that tesamorelin would increase skeletal muscle density (less fat) and skeletal muscle area, supportive of an overall improvement in muscle quality, compared to placebo.